capecitabine (Xeloda)

Subscribe to Selected New Research on capecitabine

1297 relevant articles (274 outcomes, 586 trials/studies) found for this Drug

Description: a fluorouracil prodrug; Xeloda is tradename

Also Known As:

Xeloda; N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine

Relationship Network

Drug Context: Research Results

Experts

1.	Cassidy, J: 11 articles (07/2007 - 01/2000)
2.	Twelves, C: 10 articles (04/2006 - 03/2000)
3.	Osterwalder, B: 10 articles (05/2002 - 01/2000)
4.	Cassidy, Jim: 9 articles (05/2008 - 03/2002)
5.	Chang, Heung Moon: 8 articles (10/2008 - 07/2003)
6.	Cunningham, D: 8 articles (10/2008 - 08/2003)
7.	Diasio, Robert B: 8 articles (07/2007 - 10/2002)
8.	Sakamoto, Junichi: 7 articles (09/2008 - 02/2004)
9.	Figer, Arie: 7 articles (08/2008 - 06/2004)
10.	Kang, Yoon-Koo: 7 articles (04/2008 - 07/2003)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 08/01/2007 - "PURPOSE: The oral fluoropyrimidine carbamate, capecitabine, is a highly active and well-tolerated treatment for metastatic breast cancer. " 01/01/2001 - "Capecitabine is an important new treatment option for breast cancer patients, and ongoing clinical trials should further define its role in a range of settings." 10/01/2005 - "Within the limits of phase II trial, this reduced dose of capecitabine appears as effective for advanced breast cancer as full dose capecitabine with a lower incidence of toxicity." 01/01/2001 - "Moreover, randomized, phase II studies have demonstrated that capecitabine is effective in anthracycline-pretreated patients and as first-line therapy for metastatic breast cancer. " 11/01/2009 - "CONCLUSIONS: Capecitabine, alone or in combination, is a feasible, effective treatment for breast cancer. " Order ALL the reference details at left...
2.	Colorectal Neoplasms (Colorectal Cancer) 01/01/2007 - "BACKGROUND: Capecitabine has demonstrated high efficacy as first-line treatment for metastatic colorectal cancer (mCRC). " 06/01/2004 - "PURPOSE: Capecitabine has demonstrated high efficacy as first-line treatment for metastatic colorectal cancer (MCRC). " 07/01/2006 - "As the treatment for metastatic colorectal cancer, capecitabine showed at least comparable efficacy with a favorable safety profile to bolus 5-FU/LV. " 12/01/2003 - "BACKGROUND: Oral capecitabine achieves a superior response rate with an improved safety profile compared with bolus 5-fluorouracil-leucovorin (5-FU/LV) as first-line treatment for patients with metastatic colorectal cancer. " 02/01/2004 - "We conclude that the modified Japanese intermittent regimen of capecitabine is effective and well tolerated as first-line treatment for advanced colorectal cancer, and is worthy of further study in larger phase III studies." Order ALL the reference details at left...
3.	Neoplasms (Cancer) 11/01/2003 - "Complete and sustained remission of refractory cervical cancer following a single cycle of capecitabine. " 01/01/2009 - "In the HT29 model, tumor growth inhibition and increase in life span (ILS) were significantly greater with capecitabine 7/7 than with 14/7 (P<0.05). " 02/15/1998 - "The efficacy of capecitabine would be optimized by selecting patients who have tumors with a high ratio of dThdPase to DPD activities." 01/01/2004 - "Expression of TP in tumor tissue may clinically predict efficacy of capecitabine. " 04/01/2007 - "A number of recent trials have shown that capecitabine in combination with other agents seems to be active as first-line treatment in advanced biliary cancer. " Order ALL the reference details at left...
4.	Rectal Neoplasms (Rectal Cancer) 01/01/2009 - "CONCLUSION: In patients with low lying, locally advanced rectal cancer, preoperative chemoradiation using oral capecitabine 825 mg/m2, twice a day on radiotherapy days, was tolerable and effective in downstaging and resulted in 46.5% anal sphincter preservation rate." 02/01/2006 - "CONCLUSIONS: Preoperative chemoradiation with capecitabine and RT appeared to be effective in locally advanced resectable, rectal cancer. " 09/01/2008 - "PURPOSE: The objective of this expanded phase II trial was to confirm the safety results of the preceding phase I study and establish the efficacy of neoadjuvant radiochemotherapy with capecitabine in rectal cancer in a multicenter setting. " 08/01/2007 - "OBJECTIVES: The purpose of this study was to evaluate the safety and efficacy of preoperative capecitabine and radiation therapy (RT) in patients with locally advanced rectal cancer (LARC). " 02/01/2006 - "BACKGROUND: The aim of the study was to evaluate tolerance and efficacy of preoperative treatment with capecitabine in combination with radiation therapy (RT) in patients with locally advanced, resectable, rectal cancer. " Order ALL the reference details at left...
5.	Stomach Neoplasms (Stomach Cancer) 01/01/2003 - "CONCLUSION: Capecitabine was suggested to be safe and effective in the treatment of advanced or recurrent gastric cancer. " 03/01/2009 - "Several trials have demonstrated the safety and efficacy of regimens combining capecitabine with other known active drugs against gastric cancer in doublet and triplet combinations. " 08/19/2008 - "A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer." 08/19/2008 - "This randomised multicentre phase II study was conducted to investigate the activity and safety of two oral fluoropyrimidines, capecitabine or S-1, in elderly patients with advanced gastric cancer (AGC). " 04/01/2008 - "Many promising biological agents are now being tested in Phase III trials, incorporating capecitabine combinations as control arms, in patients with advanced gastric cancer." Order ALL the reference details at left...

Related Drugs and Biologics

1.	oxaliplatin (Eloxatin)
2.	Fluorouracil (Carac)
3.	irinotecan (Camptosar)
4.	capecitabine (Xeloda)
5.	docetaxel (Taxotere)
6.	Leucovorin (Folinic Acid)
7.	gemcitabine
8.	Cisplatin (Platino)
9.	taxane
10.	XELOX

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Combination Drug Therapy (Combination Chemotherapy)
3.	Heterologous Transplantation (Xenotransplantation)
4.	Neoadjuvant Therapy
5.	Adjuvant Chemotherapy

Best Treatments:
Research Summary Report
on Breast Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 3868 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>